470 related articles for article (PubMed ID: 28666070)
1. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis.
Kim BS; Seo YS; Kim YS; Lee CH; Lee HA; Um SH; Yoo JJ; Kim SG; Suh SJ; Jung YK; Ahn SH; Han KH; Yim HJ; Kim SU;
J Gastroenterol Hepatol; 2018 Feb; 33(2):503-510. PubMed ID: 28666070
[TBL] [Abstract][Full Text] [Related]
2. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis.
Kim MN; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Song KJ; Park YN; Han KH
Hepatology; 2015 Jun; 61(6):1851-9. PubMed ID: 25643638
[TBL] [Abstract][Full Text] [Related]
4. ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis.
Kim MN; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Jang SY; Tak WY; Kweon YO; Park SY; Kim SU
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2278-2287.e5. PubMed ID: 36375797
[TBL] [Abstract][Full Text] [Related]
5. Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy.
Song BG; Sinn DH; Chi S; Kim K; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1447-1452. PubMed ID: 30063482
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B.
Jeon MY; Lee HW; Kim SU; Kim BK; Park JY; Kim DY; Han KH; Ahn SH
Liver Int; 2018 Apr; 38(4):676-686. PubMed ID: 28865176
[TBL] [Abstract][Full Text] [Related]
7. Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients.
Kim DS; Park SY; Kim BK; Park JY; Kim DY; Han KH; Lee YR; Tak WY; Kweon YO; Jung I; Han M; Kim EH; Ahn SH; Kim SU
J Korean Med Sci; 2021 Apr; 36(16):e105. PubMed ID: 33904261
[TBL] [Abstract][Full Text] [Related]
8. Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy.
Seo YS; Kim MN; Kim SU; Kim SG; Um SH; Han KH; Kim YS
Medicine (Baltimore); 2016 Mar; 95(12):e2985. PubMed ID: 27015173
[TBL] [Abstract][Full Text] [Related]
9. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status.
Kim MN; Hwang SG; Kim BK; Park JY; Kim DY; Han KH; Kim SU; Ahn SH
Gut Liver; 2019 Mar; 13(2):197-205. PubMed ID: 30602075
[TBL] [Abstract][Full Text] [Related]
10. Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis.
Shin SH; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Kim BK
Liver Int; 2015 Mar; 35(3):1054-62. PubMed ID: 24930484
[TBL] [Abstract][Full Text] [Related]
11. Addition of liver stiffness enhances the predictive accuracy of the PAGE-B model for hepatitis B-related hepatocellular carcinoma.
Chon HY; Lee HA; Suh SJ; Lee JI; Kim BS; Kim IH; Lee CH; Jang BK; Lee HW; Hwang JS; Lee CH; Lee JW; Yu JH; Seo YS; Yim HJ; Kim SU;
Aliment Pharmacol Ther; 2021 Apr; 53(8):919-927. PubMed ID: 33465253
[TBL] [Abstract][Full Text] [Related]
12. Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B.
Kim HS; Kim BK; Kim SU; Park JY; Kim DY; Song KJ; Park JW; Kim YJ; Baatarkhuu O; Han KH; Ahn SH
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1647-1656.e6. PubMed ID: 27305847
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
[TBL] [Abstract][Full Text] [Related]
14. Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis.
Chon YE; Park JY; Myoung SM; Jung KS; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH
Am J Gastroenterol; 2017 Jun; 112(6):882-891. PubMed ID: 28374814
[TBL] [Abstract][Full Text] [Related]
15. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
Kim GA; Han S; Kim HD; An J; Lim YS
J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
[TBL] [Abstract][Full Text] [Related]
16. Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance.
Park Y; Lee JH; Sinn DH; Park JY; Kim MA; Kim YJ; Yoon JH; Kim DY; Ahn SH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Clin Transl Gastroenterol; 2021 Jan; 12(1):e00290. PubMed ID: 33433118
[TBL] [Abstract][Full Text] [Related]
17. Role of Serum M2BPGi Levels in Predicting Persistence of Advanced Fibrosis in Chronic Hepatitis B Virus Infection.
Mak LY; Wong DK; Cheung KS; Hui RW; Liu F; Fung J; Seto WK; Yuen MF
Dig Dis Sci; 2022 Nov; 67(11):5127-5136. PubMed ID: 35258755
[TBL] [Abstract][Full Text] [Related]
18. Risk assessment of liver-related events using transient elastography in patients with chronic hepatitis B receiving entecavir.
Kim MN; Kim SU; Park JY; Kim DY; Han KH; Chon CY; Ahn SH
J Clin Gastroenterol; 2014 Mar; 48(3):272-8. PubMed ID: 23811938
[TBL] [Abstract][Full Text] [Related]
19. Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection.
Mak LY; Hui RW; Fung J; Liu F; Wong DK; Li B; Cheung KS; Yuen MF; Seto WK
Hepatol Int; 2021 Aug; 15(4):901-911. PubMed ID: 34152534
[TBL] [Abstract][Full Text] [Related]
20. Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B.
Chon HY; Lee JS; Lee HW; Chun HS; Kim BK; Tak WY; Park JY; Kweon YO; Kim DY; Ahn SH; Jang SY; Park SY; Kim SU
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):e794-e807. PubMed ID: 34091048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
